Elanco Animal Health has signed an agreement with Merck Animal Health to divest its rights to Vecoxan, which is used to treat coccidiosis in calves and lambs. The all-cash deal totals $55 million. This agreement is contingent on Elanco closing on its deal to acquire the Bayer Animal Health business.
Subscribe to RRFN
Get a weekly digest from RRFN to stay up-to-date on all the latest news in agriculture.